Conference Coverage
Conference Coverage
One Patient Changed This Oncologist’s View of Hope. Here’s How.
“How we think about hope directly influences patient care,” according to a professor of clinical medicine at Weill Cornell Medicine in New York...
Latest News
Surviving to Thriving: Enhancing Quality of Life in Breast Cancer
Up to 90% of early breast cancer survivors experience long-term effects from treatment, which often include fatigue, loss of mobility, chronic...
Conference Coverage
Ovarian Cancer Risk Doubled by Estrogen-Only HRT
Long-term follow up in women with hysterectomy included in the WHI reveals significantly more cases of ovarian cancer.
Latest News
Study Highlights Melanoma Survival Disparities in Rural vs Urban Settings
To characterize the rural population diagnosed with melanoma and assess associated disparities in the United States, researchers used data from...
Conference Coverage
Chemo May Benefit Some Older Patients With Metastatic Pancreatic Cancer
Researchers examine real-world outcomes of older adults with untreated metastatic pancreatic cancer.
Conference Coverage
T-DXd Moves Toward First Line for HER2-Low Metastatic BC
New results from DESTINY trials support use of the antibody-drug conjugate earlier in the treatment algorithm for cancers expressing even the...
Conference Coverage
Young People’s Gut Bacteria May Drive Colorectal Cancer Risk
Researchers found signs that a high-fat, low-fiber diet may increase inflammation in the gut that prevents it from naturally suppressing tumors....
Conference Coverage
‘Groundbreaking’ Trial Shows Survival Benefits in Lung Cancer
Presentation on treatment for limited stage small cell lung cancer draws rounds of applause at the annual meeting of the American Society of...
Conference Coverage
Neoadjuvant Checkpoint Inhibition Study Sets New Standard of Care in Melanoma
Results of the first phase 3 oncology study to test checkpoint inhibition without chemotherapy were presented at the annual meeting of the...
Conference Coverage
New Drug Combo Boosts PFS
Patients with Hodgkin lymphoma fared better on a less toxic alternative to gold-standard BrECADD therapy.
